Tevogen Bio Holdings Inc. - TVGN STOCK NEWS

Tevogen Bio (Nasdaq: TVGN) announced it will host a panel discussion titled 'Pioneering the Economics of Health: Balancing Access and Outcomes' during the 43rd Annual J.P. Morgan Healthcare Conference. The event, scheduled for January 13, 2025, will be held at the Marines' Memorial Club & Hotel in San Francisco.

The panel will feature distinguished healthcare leaders discussing critical aspects of the healthcare ecosystem, including:

• U.S. leadership challenges in healthcare innovation
• Impact of cost-containment measures and the Inflation Reduction Act
• Implications of new administration's healthcare approach on global markets

Panelists include executives from Simon-Kucher, Department of Veterans Affairs, Rubix Health, Tufts Center, and Tevogen Bio leadership. The discussion will run from 3:15 PM to 4:00 PM PST, followed by a reception until 6:00 PM.

Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference, scheduled for January 13-16, 2025, in San Francisco, will be attended by Tevogen's Founder and CEO Ryan Saadi, MD, MPH.

The company, which specializes in developing off-the-shelf, genetically unmodified T cell therapeutics for infectious diseases and cancers, will be part of what is recognized as the industry's largest and most informative healthcare investment symposium. The event brings together key stakeholders to discuss healthcare innovations and advancements.

Victor Sordillo, Board Member of Tevogen Bio (Nasdaq: TVGN), has been inducted into The New Jersey League of Municipalities Hall of Fame for his 24 years of continuous service as Warren Township Committee Member. During his tenure as Mayor, Warren Township achieved significant developments including the construction of a new library, town hall, youth facilities, and the acquisition of approximately 1,000 acres of open space.

Under his leadership, Warren Township maintained a AAA bond rating while keeping long-term debt at one-tenth of the state-allowable limit. The township received notable recognition, being ranked sixth best place to live in America by Money magazine and second-best place to live in Central NJ by New Jersey Monthly.

Tevogen Bio (Nasdaq: TVGN) announced organizational changes to support growth, including expanded responsibilities for key leaders. The company reported significant financial improvements with a $52.5 million reduction in net loss and sufficient capital for 33 months of operations. Revenue forecasts project $1 billion in launch year for oncology with 5-year estimates of $10-14 billion, and specialty care projections of nearly $1 billion in launch year with 5-year estimates of $18-22 billion. The company signed a Letter of Intent with CD8 Technology for a $50 million R&D and manufacturing facility. Notably, Tevogen maintains 78% founding team ownership, contrasting with industry norms of around 5%.

Tevogen Bio (Nasdaq: TVGN), a clinical-stage biotech company, has reported significant financial improvements in Q3 2024, including a $52.5 million reduction in net loss and elimination of nearly all liabilities. The company has confirmed sufficient capital to fund operations for the next 33 months. CEO Ryan Saadi emphasized the company's commitment to preserving shareholder value while addressing concerns about short-selling activities affecting the company's stock. Management is actively monitoring potential short-selling activities and plans to work with authorities as needed.

Tevogen Bio (Nasdaq: TVGN) reported improved Q3 2024 financial results, reducing net loss to $4.3 million from $56.8 million in the previous year. The company significantly improved its financial position by reducing liabilities from $99.9 million to $10.5 million. While internal valuations estimate IP and product assets at over $10 billion, these assets remain unreported on balance sheets due to US GAAP rules. The company has secured funding for the next 33 months through a loan agreement. Notably, approximately 78% of equity is retained by company officers, compared to an industry average of 4%.

Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, is preparing to file its quarterly financials. The company, founded in 2020, has developed a significant asset portfolio while maintaining expenditures under $40 million. CEO Ryan Saadi highlighted the company's focus on preserving shareholder value while managing growth, noting potential warrant conversion at $11.50 per share could provide over $200 million in capital. The company is currently planning R&D and manufacturing site development.

Tevogen Bio (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech, is preparing to file its quarterly financials. The company, founded in 2020, has built a significant asset portfolio while maintaining expenditures below $40 million. CEO Ryan Saadi emphasized the importance of balancing growth with shareholder value preservation, particularly noting the potential equity dilution from warrant conversion at $11.50 per share. The company is currently developing plans for R&D and manufacturing facilities while focusing on sustainable business practices.

Tevogen Bio (Nasdaq: TVGN) is approaching finalization of an agreement with CD8 Technology for a turn-key facility to support pre-clinical research and GMP manufacturing capabilities. The company has confirmed access to a $36 million line of credit to maintain operations and support growth. The clinical-stage biotech, which develops off-the-shelf T cell therapeutics for infectious diseases and cancers, operates without substantial debt and maintains adequate cash reserves. Management emphasizes their commitment to maintaining shareholder value while focusing on operational progress and delivering affordable therapies.